Abstract：
OBJECTIVE: Autoantibodies against hexokinase 1 (HK1) were recently proposed to be associated with diabetic macular edema (DME). We hypothesized that anti-HK1 autoantibodies can be used as DME markers and to predict DME onset.
METHODS: Serum from patients with 1) DME, 2) diabetes mellitus (DM), 3) allergies or autoimmunities, and 4) control subjects was tested for anti-HK1 and anti-hexokinase 2 (HK2) autoantibodies by immunoblotting. Patients with DM were prospectively followed for up to nine years, and the association of anti-HK1 antibodies with new-onset DME was evaluated. The vitreous humor was also tested for autoantibodies.
RESULTS: Among patients with DME, 32 % were positive for anti-HK1 autoantibodies (42 % of those with underlying type 1 DM and 31 % of those with underlying type 2 DM), and 12 % were positive for anti-HK2 autoantibodies, with only partial overlap of these two groups of patients. Anti-HK1 positive were also 7 % of patients with DM, 6 % of patients with allergies and autoimmunities, and 3 % of control subjects. The latter three groups were anti-HK2 negative. Only one of seven patients with DM who were initially anti-HK1 positive developed DME.
CONCLUSIONS: Anti-HK1 autoantibodies can be used as DME markers but fail to predict DME onset.
METHODS: Serum from patients with 1) DME, 2) diabetes mellitus (DM), 3) allergies or autoimmunities, and 4) control subjects was tested for anti-HK1 and anti-hexokinase 2 (HK2) autoantibodies by immunoblotting. Patients with DM were prospectively followed for up to nine years, and the association of anti-HK1 antibodies with new-onset DME was evaluated. The vitreous humor was also tested for autoantibodies.
RESULTS: Among patients with DME, 32 % were positive for anti-HK1 autoantibodies (42 % of those with underlying type 1 DM and 31 % of those with underlying type 2 DM), and 12 % were positive for anti-HK2 autoantibodies, with only partial overlap of these two groups of patients. Anti-HK1 positive were also 7 % of patients with DM, 6 % of patients with allergies and autoimmunities, and 3 % of control subjects. The latter three groups were anti-HK2 negative. Only one of seven patients with DM who were initially anti-HK1 positive developed DME.
CONCLUSIONS: Anti-HK1 autoantibodies can be used as DME markers but fail to predict DME onset.
摘要：
目的：最近提出抗己糖激酶1（HK1）的自身抗体与糖尿病性黄斑水肿（DME）有关。我们假设抗HK1自身抗体可用作DME标志物并预测DME发病。
方法：来自1）DME患者的血清，2）糖尿病（DM），3）过敏或自身免疫，和4)通过免疫印迹测试对照受试者的抗HK1和抗己糖激酶2(HK2)自身抗体。对DM患者进行了长达9年的前瞻性随访，并评估了抗HK1抗体与新发DME的相关性。还测试了玻璃体液的自身抗体。
结果：在DME患者中，32％的抗HK1自身抗体呈阳性（42％的潜在1型DM患者和31％的潜在2型DM患者），12％的抗HK2自身抗体阳性，两组患者仅部分重叠。抗HK1阳性也占DM患者的7%，6％的患者有过敏和自身免疫，和3%的对照受试者。后三组抗HK2阴性。最初抗HK1阳性的7例DM患者中只有1例发展为DME。
结论：抗HK1自身抗体可用作DME标志物，但不能预测DME的发病。
方法：来自1）DME患者的血清，2）糖尿病（DM），3）过敏或自身免疫，和4)通过免疫印迹测试对照受试者的抗HK1和抗己糖激酶2(HK2)自身抗体。对DM患者进行了长达9年的前瞻性随访，并评估了抗HK1抗体与新发DME的相关性。还测试了玻璃体液的自身抗体。
结果：在DME患者中，32％的抗HK1自身抗体呈阳性（42％的潜在1型DM患者和31％的潜在2型DM患者），12％的抗HK2自身抗体阳性，两组患者仅部分重叠。抗HK1阳性也占DM患者的7%，6％的患者有过敏和自身免疫，和3%的对照受试者。后三组抗HK2阴性。最初抗HK1阳性的7例DM患者中只有1例发展为DME。
结论：抗HK1自身抗体可用作DME标志物，但不能预测DME的发病。
